Study type:
Study number:
Type of treatment:
Allogeneic
Diseases:
Complications: infectious
Short title:
Survey on extended Letermovir prophylaxis
Primary objective:
Asses the number of allogeneic patients receiving Letermovir for more than 270 days
Key inclusion criteria:
Centres performing allogeneic HCT
Country:
All EBMT member countries
Principal investigator:
Jan Styczynski
EBMT Study coordinator:
Nina Knelange
Study coordinator email:
idwp@ebmt.org
EBMT Study Unit:
Leiden Study Unit
Reason for processing personal data:
Not applicable to surveys
Categories of personal data collected:
Not applicable to surveys
Recipients who may access the data:
Not applicable to surveys
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
Not applicable to surveys
Privacy notices
Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)
Data Protection Impact Assessments
Rights available to individuals:
Access
Data portability
Rectification
Objection
Deletion
Is a Data Protection Impact Assessment required?:
Not applicable to surveys
Retention Schedule (if possible):
Not applicable to surveys